Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0026827 (
hypotonia
)
5,860
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Glycogen storage disease type IV (GSD-IV) is a rare autosomal recessive disease caused by a deficiency of
glycogen branching enzyme
(
GBE
) activity. This results in the accumulation of abnormal glycogen in the liver and other organs. We report the case of a 14-month-old female patient with typical hepatic pathologic findings of GSD-IV. The patient suffered from
decreased muscle tone
and progressive hepatosplenomegaly since birth. A wedge biopsy of the liver showed enlarged hepatocytes with colorless to faintly eosinophilic ground glass intracytoplasmic inclusions. Portal fibrosis and lobular, fibrous septa were present. Ultrastructure of the inclusions revealed non-membrane-bound fibrillar material 5 nm in maximal diameter. Enzyme study revealed a total deficiency of
GBE
activity.
...
PMID:Glycogen storage disease type IV: a case report. 1053 7
We report of an infant with neonatal
glycogen storage disease type IV
(
GSD IV
) who was examined for severe
hypotonia
and cardiomyopathy. On the muscle biopsy there were many fibers with diastase-resistant polyglucosan bodies.
Glycogen branching enzyme
(
GBE1
) activity in the muscle was markedly reduced. The infant had a homozygous single nucleotide deletion in the open reading frame of
GBE1
gene.
...
PMID:A neonatal form of glycogen storage disease type IV. 1291 6
Glycogen storage disease type IV (GSD-IV) is an autosomal recessive genetic disorder due to a deficiency in the activity of the
glycogen branching enzyme
(
GBE
). A deficiency in
GBE
activity results in the accumulation of glycogen with fewer branching points and long, unbranched outer chains. The disorder results in a variable phenotype, including musculoskeletal, cardiac, neurological, and hepatic involvement, alone or in continuum, which can be identified at any stage of life. The classic form of GSD-IV is a hepatic presentation, which presents in the first 18 months of life with failure to thrive, hepatomegaly, and cirrhosis that progresses to liver failure, resulting in death by age 5 years. A severe congenital musculoskeletal phenotype with death in the neonatal period has also been described. We report an unusual case of congenital musculoskeletal presentation of GSD-IV with stable congenital
hypotonia
, gross motor delay, and severe fibro-fatty replacement of the musculature, but no hepatic or cardiac involvement. Molecular analysis revealed two novel missense mutations with amino acid changes in the
GBE
gene (Q236H and R262C), which may account for the mild phenotype.
...
PMID:Non-lethal congenital hypotonia due to glycogen storage disease type IV. 1652 37
Glycogen branching enzyme
deficiency (
glycogen storage disease type IV
, GSD-IV) is a rare autosomal recessive disorder of the glycogen synthesis with high mortality. Two female newborns showed severe
hypotonia
at birth and both died of cardiorespiratory failure, at 4 and 12 weeks, respectively. In both patients, muscle biopsies showed deposits of PAS-positive diastase-resistant material and biochemical analysis in cultured fibroblasts showed markedly reduced
glycogen branching enzyme
activity. Direct sequencing of
GBE1
gene revealed that patient 1 was homozygous for a novel c.691+5 g>c in intron 5 (IVS5+5 g>c). RT-PCR analysis of
GBE1
transcripts from fibroblasts cDNA showed that this mutation produce aberrant splicing. Patient 2 was homozygous for a novel c.1643G>A mutation leading to a stop at codon 548 in exon 13 (p.W548X). These data underscore that in GSD-IV a severe phenotype correlates with null mutations, and indicate that RNA analysis is necessary to characterize functional consequences of intronic mutations.
...
PMID:Null mutations and lethal congenital form of glycogen storage disease type IV. 1766 46
A diagnosis of GSD-IV was established in three premature, floppy infants based on characteristic, however unusually pleomorphic polyglucosan bodies at the electron microscopic level,
glycogen branching enzyme
deficiency in two cases, and the identification of
GBE1
mutations in two cases. Pleomorphic polyglucosan bodies in muscle fibers and macrophages, and less severe in Schwann cells and microglial cells were noted. Most of the inclusions were granular and membrane-bound; others had an irregular contour, were more electron dense and were not membrane bound, or homogenous ('hyaline'). A paracrystalline pattern of granules was repeatedly noted showing a periodicity of about 10 nm with an angle of about 60 degrees or 120 degrees at sites of changing linear orientation. Malteser crosses were noted under polarized light in the larger inclusions. Some inclusions were PAS positive and others were not. Severely atrophic muscle fibers without inclusions, but with depletion of myofibrils in the plane of section studied indicated the devastating myopathic nature of the disease. Schwann cells and peripheral axons were less severely affected as was the spinal cord. Two novel protein-truncating mutations (c.1077insT, p.V359fsX16; g.101517_127067del25550insCAGTACTAA, DelExon4-7) were identified in these families. The present findings extend previous studies indicating that truncating
GBE1
mutations cause a spectrum of severe diseases ranging from generalized intrauterine hydrops to fatal perinatal
hypotonia
and fatal cardiomyopathy in the first months of life.
...
PMID:Congenital type IV glycogenosis: the spectrum of pleomorphic polyglucosan bodies in muscle, nerve, and spinal cord with two novel mutations in the GBE1 gene. 1866 Nov 38
Glycogen storage disease type IV (
GSD IV
, or Andersen disease) is an autosomal recessive disorder due to the deficiency of
1,4-alpha-glucan branching enzyme
(or
glycogen branching enzyme
,
GBE1
), resulting in an accumulation of amylopectin-like polysaccharide in muscle, liver, heart and central and peripheral nervous system. Typically, the presentation is in childhood with liver involvement up to cirrhosis. The neuromuscular form varies in onset (congenital, perinatal, juvenile and adult) and in severity. Congenital cases are rare, and fewer than 20 cases have been described and genetically determined so far. This form is characterized by polyhydramnios, neonatal
hypotonia
, and neuronal involvement; hepatopathy is uncommon, and the babies usually die between 4 weeks and 4 months of age. We report the case of an infant who presented severe
hypotonia
, dilatative cardiomyopathy, mild hepatopathy, and brain lateral ventricle haemorrhage, features consistent with the congenital form of
GSD IV
. He died at one month of life of cardiorespiratory failure. Muscle biopsy and heart and liver autoptic specimens showed many vacuoles filled with PAS-positive diastase-resistant materials. Electron-microscopic analysis showed mainly polyglucosan accumulations in all the tissues examined. Postmortem examination showed the presence of vacuolated neurons containing this abnormal polysaccharide.
GBE1
biochemical activity was virtually absent in muscle and fibroblasts, and totally lacking in liver and heart as well as glycogen synthase activity.
GBE1
gene sequence analysis revealed a novel homozygous nonsense mutation, p.E152X, in exon 4, correlating with the lack of enzyme activity and with the severe neonatal involvement. Our findings contribute to increasing the spectrum of mutation associated with congenital
GSD IV
.
...
PMID:Neuropathological study of skeletal muscle, heart, liver, and brain in a neonatal form of glycogen storage disease type IV associated with a new mutation in GBE1 gene. 1935 89
The fatal infantile neuromuscular presentation of branching enzyme deficiency (
glycogen storage disease type IV
) due to mutations in the gene encoding the
glycogen branching enzyme
, is a rare but probably underdiagnosed cause of congenital
hypotonia
. We report an infant girl with severe generalized
hypotonia
, born at 33 weeks gestation who required ventilatory assistance since birth. She had bilateral ptosis, mild knee and foot contractures and echocardiographic evidence of cardiomyopathy. A muscle biopsy at 1 month of age showed typical polyglucosan storage. The autopsy at 3.5 months of age showed frontal cortex polymicrogyria and polyglucosan bodies in neurons of basal ganglia, thalamus, substantia innominata, brain stem, and myenteric plexus, as well as liver involvement.
Glycogen branching enzyme
activity in muscle was virtually undetectable. Sequencing of the
GBE1
gene revealed a homozygous 28 base pair deletion and a single base insertion at the same site in exon 5. This case confirms previous observations that
GBE
deficiency ought to be included in the differential diagnosis of congenital
hypotonia
and that the phenotype correlates with the 'molecular severity' of the mutation.
...
PMID:Branching enzyme deficiency/glycogenosis storage disease type IV presenting as a severe congenital hypotonia: muscle biopsy and autopsy findings, biochemical and molecular genetic studies. 2083 45
Anderson disease, also known as
glycogen storage disease type IV
(MIM 232500), is a rare autosomal recessive disorder caused by a deficiency of
glycogen branching enzyme
. Glycogen storage disease type IV has a broad clinical spectrum ranging from a perinatal lethal form to a nonprogressive later-onset disease in adults. Here, we report 2 unrelated infants who were born small for their gestational age and who had profound
hypotonia
at birth and thus needed mechanical ventilation. Both of these patients shared the same frameshift mutation (c.288delA, pGly97GlufsX46) in the
GBE1
gene. In addition, both of these patients were found to have 2 different large deletions in the
GBE1
gene; exon 7 and exons 2 to 7, respectively, on the other alleles. This case report also highlights the need for a more comprehensive search for large deletion mutations associated with
glycogen storage disease type IV
, especially if routine
GBE1
gene sequencing results are equivocal.
...
PMID:Association of the congenital neuromuscular form of glycogen storage disease type IV with a large deletion and recurrent frameshift mutation. 2191 43
A total of 11 types of glycogen storage disorders have been recognized with variable clinical presentations. Type IV, also known as Andersen disease, represents a rare subtype that can induce severe clinical findings early in life. We report on a patient with early fetal onset of symptoms with severe neuromuscular findings at birth. The pregnancy was further complicated by polyhydramnios and depressed fetal movement. At birth severe
hypotonia
was noticed requiring active resuscitation and then mechanical ventilation. His lack of expected course for hypoxic ischemic encephalopathy prompted genetic testing, including a muscle biopsy, which confirmed the diagnosis of glycogen storage disease IV (
GSD IV
). Mutation analysis of the
glycogen branching enzyme
1 gene demonstrated a previously unrecognized mutation. We review recent information on early presentation of
GSD IV
with particular interest in the presentation of the neonatal lethal neuromuscular form of this rare disorder.
...
PMID:Neonatal presentation of lethal neuromuscular glycogen storage disease type IV. 2301 86
Glycogen storage disease type IV (
GSD IV
) is an autosomal recessive disorder causing polyglucosan storage in various tissues. Neuromuscular forms present with fetal akinesia deformation sequence, lethal myopathy, or mild
hypotonia
and weakness. A 3-year-old boy presented with arthrogryposis, motor developmental delay, weakness, and rigid spine. Whole body MRI revealed fibroadipose muscle replacement but sparing of the sartorius, gracilis, adductor longus and vastus intermedialis muscles. Polyglucosan bodies were identified in muscle, and
GBE1
gene analysis revealed two pathogenic variants. We describe a novel neuromuscular
GSD IV
phenotype and confirm the importance of muscle morphological studies in early onset neuromuscular disorders.
...
PMID:A novel neuromuscular form of glycogen storage disease type IV with arthrogryposis, spinal stiffness and rare polyglucosan bodies in muscle. 2754 58
1
2
Next >>